InvestorsHub Logo

petemantx

05/12/20 8:15 PM

#296662 RE: GreenBioAnalyst #296660

Who in IPIX is going to establish the clinical trials procedures, end points, etc for human trials for CV19? Leo is not medically trained and I am not sure if Ms. Harness has the knowledge to lead in such matters.

Maybe IPIX hires a medical professional to do such work and pays a fixed amount of shares, maybe the INH,FDA,or other regulatory agencies have trial procedures already established? Hard to believe the top tier of drugs already approved by the FDA didn't have at least one advance to human trials as an anti-viral or anti-inflammatory such that trial procedures were established.

There should be a large number of very good hospitals across the country that could run the tests as all in metropolitan areas have large numbers of CV patients so finding subjects and test site should be no problem.

So where does BP fit in as a sponsor as to the role they are supposed to play?

If above is true that sites and trial procedures have already been established, and we know Brilacidin is now available in quantity to proceed with such trials, human trials should be able to start pretty quickly once the labs give the OK from the lung tissue tests.

My thinking is that there has to be a "standardized" trial for CV drugs because different trial procedures and criteria could lead to different results and allow a lesser drug to get better results than a more powerful drug. I believe Brilacidin is the most powerful drug out there for CV and I don't want to see it get bettered because the playing field wasn't level regarding the human trials.

PJ007

05/12/20 8:15 PM

#296663 RE: GreenBioAnalyst #296660

GreenBio, your thoughts and explanations are a breath of fresh air. Much appreciated!!!!

To infinity and beyond!

05/13/20 6:35 AM

#296672 RE: GreenBioAnalyst #296660

It ain't so simple.

Perhaps the crime-your word yesterday was criminals- is excessive optimism. Thorough diligence does not mean the drug will work, sorry. What would you have said about B OM, before and after the initial results? Only to find out in December 2018 that the final data have not been good enough to get any deal at all with big Pharma? All the due diligence, including actual hamster animal models from Sonis, suggested a win for B OM, but here we are, with nothing to show for that very promising application of Brilacidin.

It ain't so simple.

To pretend that the RBL lung studies etc etc will all be good is outright wrong. They might be good and they might not be. This may be the start of shocking good luck for IP, ormaybe in a month you will find that today's shares are 3x what they oughta be.

One cannot know that the results will be great because they may well not be, and it is not a crime to say so.

MXAMDUD

05/13/20 9:03 AM

#296686 RE: GreenBioAnalyst #296660

I'll take the other side of the bet and say IPIX gets nothing for B other than a fluffy PR. BP would know all about B if it had anywhere near the effectiveness you claim. these $30/share pie in the sky calls are misleading and dangerous. THis POS will be lucky to ever get over .50/share again.

we sit at .15 and drifting down as another week is lost